San Diego, USA – SeekIn, a global leader in blood‑based cancer detection, today announced the availability of its OncoSeek® multi‑cancer early detection test at the Centro de Investigación en Cirugía y Cáncer (Cicica) of the University of Costa Rica (UCR), marking the first public center in Central America and the Caribbean to offer this innovative technology. OncoSeek® is designed to help identify cancer risk at an early, often asymptomatic stage, using a tube of blood.
OncoSeek® analyzes a panel of protein tumor markers in combination with clinical factors through a proprietary algorithm to generate an alert for the possible presence of cancer and an indication of the most likely tissue of origin. The test can flag risk for 14 common cancer types, including bile duct, breast, cervix, colorectum, endometrium, esophagus, gallbladder, head and neck, liver, lung, lymphoma, ovary, pancreas, and stomach, as a complement to standard diagnostic pathways. It is intended primarily for individuals at increased risk of cancer, such as adults over 50, smokers, people with a family history of cancer, metabolic or inflammatory conditions, or known genetic predisposition.
In previously published international studies including more than 15,000 cases, OncoSeek® has demonstrated a favorable balance of sensitivity and specificity as a screening‑oriented tool for cancer risk assessment. When repeated periodically in higher‑risk individuals, such an approach has the potential to support earlier diagnosis, more timely treatment, and improved outcomes.
Through the collaboration with Cicica‑UCR, OncoSeek® will be integrated into a multidisciplinary care and research framework, enabling appropriate follow‑up with imaging, pathology, and specialist referral whenever the test flags an elevated risk. This partnership underscores SeekIn’s commitment to making advanced, accessible cancer detection technologies available in regions where affordability and implementation feasibility are critical for broad adoption. OncoSeek® is already available in Brazil, Bulgaria, China, Colombia, Mexico, the Netherlands, Nigeria, Pakistan, Poland, and El Salvador.
The press release from Cicica‑UCR can be found at https://www.ucr.ac.cr/noticias/2026/1/13/la-prueba-para-la-deteccion-ultratemprana-de-nueve-tipos-de-cancer-ya-esta-disponible-en-la-ucr.html.